N-phenyl-2-naphthalenamine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 8679 |
CHEMBL ID | 1543632 |
CHEBI ID | 34877 |
SCHEMBL ID | 38433 |
SCHEMBL ID | 6435930 |
MeSH ID | M0058609 |
Synonym |
---|
AC-13068 |
BIDD:ER0357 |
smr000112180 |
antioxidant 116 |
neosone d |
agerite powder |
2-phenylaminonaphthalene |
nsc-37151 |
nonox dn |
2-naphthylamine, n-phenyl- |
antioxidant pbn |
stabilizator ar |
nonox d |
phenyl-2-naphthylamine |
pbna |
nci-c02915 |
.beta.-naphthylphenylamine |
aceto pbn |
neozone |
n-phenyl-.beta.-naphthylamine |
wln: l66j cmr |
anilinonaphthalene |
135-88-6 |
nsc37151 |
neozon d |
2-naphthalenamine, n-phenyl- |
2-naphthylphenylamine |
n-phenyl-2-naphthylamine |
vulkanox pbn |
nilox pbna |
mls002608023 , |
n-(2-naphthyl)aniline |
neozone d |
2-anilinonaphthalene |
phenyl-.beta.-naphthylamine |
phenyl-beta-naphthylamine |
ai3-00068 |
ak 1 (stabilizer) |
fenyl-beta-naftylamin [czech] |
n-beta-naphthyl-n-phenylamine |
nocrac d |
ac eto pbn |
n-phenyl-beta-naphthylamine |
2-(n-phenylamino)naphthalene |
n-fenyl-2-aminonaftalen [czech] |
brn 2211188 |
n-(2-naphthyl)-n-phenylamine |
noclizer d |
hsdb 2888 |
phenyl-beta-naphtilamine |
nsc 37151 |
n-phenyl-2-naphthalenamine |
n-2-naphthylaniline |
naftam 2 |
beta-naphthylphenylamine |
ccris 853 |
stabilizer ar |
einecs 205-223-9 |
n-phenyl-.beta.-amino-naphthalene |
n-phenylnaphthalen-2-amine |
OPREA1_737712 |
NCGC00091111-01 |
inchi=1/c16h13n/c1-2-8-15(9-3-1)17-16-11-10-13-6-4-5-7-14(13)12-16/h1-12,17 |
STK367409 |
n-phenyl-2-naphthylamine, 97% |
NCGC00091111-02 |
P0198 |
AKOS001426472 |
A807001 |
NCGC00091111-05 |
NCGC00091111-04 |
NCGC00091111-03 |
BBL000386 |
dtxsid4021131 , |
tox21_302900 |
dtxcid601131 |
NCGC00256440-01 |
cas-135-88-6 |
NCGC00259440-01 |
tox21_201891 |
unii-456kt854aj |
456kt854aj , |
n-fenyl-2-aminonaftalen |
4-12-00-03128 (beilstein handbook reference) |
fenyl-beta-naftylamin |
2-naphthylamine, n-phenyl- [hsdb] |
n-phenyl-2-naphthylamine [iarc] |
phenyl-(beta)-naphthylamine |
2-naphthylaniline |
SCHEMBL38433 |
SCHEMBL6435930 |
CHEBI:34877 , |
W-108255 |
n-.beta.-naphthyl-n-phenylamine |
stabilator ar |
fenyl-.beta.-naftylamin |
CHEMBL1543632 |
mfcd00004052 |
antioxygene mc |
n-phenyl-beta -naphthylamine |
n-beta -naphthyl-n-phenylamine |
p.b.n |
fenyl-beta -naftylamin |
stabilator a.r |
phenyl-beta -naphthylamine |
beta -naphthylphenylamine |
nonox dnstabilizer ar |
VS-00607 |
Q13872172 |
n(c1=cc=cc=c1)c2=cc=c3c=cc=cc3=c2 |
EN300-18026 |
FT-0722125 |
F87478 |
Z57127516 |
Excerpt | Relevance | Reference |
---|---|---|
" Calculations based on Druckery and Küpfmüller's equation (1948) and present data indicate that, for dogs to form BNA tumours through exposure to a relatively high dose-level of PBNA, the period of daily dosing would occupy, or even exceed, the normal life-span." | ( Dephenylation of N-phenyl-2-naphthylamine in dogs and its possible oncogenic implications. Batten, PL; Hathway, DE, 1977) | 0.26 |
Class | Description |
---|---|
naphthalenes | Any benzenoid aromatic compound having a skeleton composed of two ortho-fused benzene rings. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 6.3096 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
Chain A, HADH2 protein | Homo sapiens (human) | Potency | 35.7168 | 0.0251 | 20.2376 | 39.8107 | AID886; AID893 |
Chain B, HADH2 protein | Homo sapiens (human) | Potency | 35.7168 | 0.0251 | 20.2376 | 39.8107 | AID886; AID893 |
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 27.0208 | 0.0072 | 15.7588 | 89.3584 | AID1224835 |
acid sphingomyelinase | Homo sapiens (human) | Potency | 25.1189 | 14.1254 | 24.0613 | 39.8107 | AID504937 |
thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 28.1877 | 0.1000 | 20.8793 | 79.4328 | AID588453; AID588456 |
BRCA1 | Homo sapiens (human) | Potency | 15.8489 | 0.8913 | 7.7225 | 25.1189 | AID624202 |
pregnane X receptor | Rattus norvegicus (Norway rat) | Potency | 44.6684 | 0.0251 | 27.9203 | 501.1870 | AID651751 |
hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 56.7004 | 3.1890 | 29.8841 | 59.4836 | AID1224846; AID1224894 |
RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 6.4617 | 0.0060 | 38.0041 | 19,952.5996 | AID1159521; AID1159523 |
TDP1 protein | Homo sapiens (human) | Potency | 22.7265 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 21.1019 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
AR protein | Homo sapiens (human) | Potency | 31.2158 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID588516; AID743035; AID743042; AID743054; AID743063 |
Smad3 | Homo sapiens (human) | Potency | 6.3096 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
caspase 7, apoptosis-related cysteine protease | Homo sapiens (human) | Potency | 76.4895 | 0.0133 | 26.9810 | 70.7614 | AID1346978 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 31.6228 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 51.3540 | 0.0006 | 57.9133 | 22,387.1992 | AID1259378 |
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 30.7072 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224839; AID1224893 |
progesterone receptor | Homo sapiens (human) | Potency | 33.0007 | 0.0004 | 17.9460 | 75.1148 | AID1346784; AID1346795 |
glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 54.7462 | 0.0002 | 14.3764 | 60.0339 | AID720691; AID720692 |
retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 3.9327 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159553; AID1159555 |
retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 11.6395 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531 |
estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 19.3343 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403 |
pregnane X nuclear receptor | Homo sapiens (human) | Potency | 30.8936 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982; AID720659 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 14.9288 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID1259248; AID1259383; AID743069; AID743075; AID743079; AID743080; AID743091 |
peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 54.9477 | 0.0010 | 19.4141 | 70.9645 | AID743191 |
caspase-3 | Homo sapiens (human) | Potency | 76.4895 | 0.0133 | 26.9810 | 70.7614 | AID1346978 |
aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 39.0277 | 0.0007 | 23.0674 | 1,258.9301 | AID651777; AID743085; AID743122 |
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 27.3476 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 55.2487 | 0.0016 | 28.0151 | 77.1139 | AID1224843; AID1224895 |
activating transcription factor 6 | Homo sapiens (human) | Potency | 51.8088 | 0.1434 | 27.6121 | 59.8106 | AID1159516 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 54.7966 | 19.7391 | 45.9784 | 64.9432 | AID1159509 |
v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 35.3882 | 0.0578 | 21.1097 | 61.2679 | AID1159526; AID1159528 |
Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 106.5835 | 0.0391 | 47.5451 | 146.8240 | AID1224845 |
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 12.5893 | 0.0018 | 15.6638 | 39.8107 | AID894 |
chromobox protein homolog 1 | Homo sapiens (human) | Potency | 63.0957 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 0.3162 | 0.0100 | 39.5371 | 1,122.0200 | AID588547 |
nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 20.5962 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 25.1189 | 0.0178 | 9.6374 | 44.6684 | AID588834 |
thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 67.7388 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
histone deacetylase 9 isoform 3 | Homo sapiens (human) | Potency | 35.3195 | 0.0376 | 17.0823 | 61.1927 | AID1259364; AID1259388 |
heat shock protein beta-1 | Homo sapiens (human) | Potency | 50.9256 | 0.0420 | 27.3789 | 61.6448 | AID743210; AID743228 |
nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 31.0625 | 0.0006 | 27.2152 | 1,122.0200 | AID651741; AID720636; AID743202; AID743219 |
Vpr | Human immunodeficiency virus 1 | Potency | 17.7828 | 1.5849 | 19.6264 | 63.0957 | AID651644 |
cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 25.1189 | 0.0316 | 10.2792 | 39.8107 | AID884; AID885 |
lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 12.5893 | 0.0200 | 10.7869 | 31.6228 | AID912 |
Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 7.8713 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 68.6293 | 0.0023 | 19.5956 | 74.0614 | AID651631; AID720552 |
Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 7.8713 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Nuclear receptor ROR-gamma | Homo sapiens (human) | Potency | 2.9849 | 0.0266 | 22.4482 | 66.8242 | AID651802 |
Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 0.8913 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) | Potency | 8.9125 | 3.9811 | 46.7448 | 112.2020 | AID720708 |
GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 34.1666 | 0.0119 | 17.9420 | 71.5630 | AID651632; AID720516 |
Ataxin-2 | Homo sapiens (human) | Potency | 34.1666 | 0.0119 | 12.2221 | 68.7989 | AID651632 |
Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 25.1189 | 1.0000 | 12.2248 | 31.6228 | AID885 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 16 (42.11) | 18.7374 |
1990's | 2 (5.26) | 18.2507 |
2000's | 9 (23.68) | 29.6817 |
2010's | 9 (23.68) | 24.3611 |
2020's | 2 (5.26) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (61.91) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 4 (9.30%) | 6.00% |
Case Studies | 1 (2.33%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 38 (88.37%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |